Park City, Utah (PRWEB) July 01, 2013
Guardsman Scientific, LLC., a cardiac ultrasound and data analytics company has engaged the Bay Tower Group and ClearCap Strategic Advisors to seek a strategic licensing partner, or acquirer to further develop its technology.
Guardsman has developed and patented a unique, non-invasive system that is designed to identify, monitor and manage patients who are known to have, or who are at-risk of developing, congestive heart failure (“CHF”), and its associated complications. The Guardsman’s Echocardiography Management System (“GEMS”) has been clinically validated for using ultrasound generated data points of cardiac function and providing recommended hemodynamic management strategies for the patient. According to Daniel Vezina, MD, founder and inventor of the technology, GEMS is able to assess a wide spectrum of functional clinical parameters of the heart.
“We view this technology as transformational, and we base this on clinical data, which has demonstrated a material reduction in the incidence of post-operative CHF, compared with standard hemodynamic management; a reduction in the hospital length of stay; and a reduction in the incidence of atrial fibrillation,” stated Jessica Smith, MS, RAC, co-founder of Guardsman Scientific.
Alan Marrullier, Managing Director at ClearCap stated the ideal partner is an existing manufacturer of cardiac ultrasound products or bedside monitors who can integrate the GEMS technology into its existing product lines in order to present its clients a truly distinctive functionality.
GEMS consists of software, a hands-free transducer and a disposable patient securing ‘patch’ system. The patient securing patch represents a highly profitably and recurring revenue stream. The Company has also developed systems and software to capture and process “big data” analytics, and is working to develop a GEMS product that can be used in animal health.
“GEMS is strategically aligned with the new healthcare reform objectives of reducing hospital costs and improving patient outcomes by reducing the rate of hospital readmission following surgery, by reducing CHF-related length of hospital stay, and improving a hospital’s Co-morbidity Mixed Index,” stated Bay Tower Group’s Jim Sergi.
“We believe GEMS would provide the right strategic partner with an innovative ultrasound platform and patient management system that would serve as a catalyst to unlock the power and value of all existing ultrasound products and bedside monitors,” stated Alan Marrullier. Moreover, GEMS could fundamentally change the practice of echocardiography and medicine by providing a patient-centric clinical tool that is applicable to the full cardiac care continuum.
About Guardsman Scientific, LLC
Guardsman Scientific is a medical device company developing innovative solutions to address congestive heart failure (CHF). Guardsman’s technology, GEMS, is comprised of a proprietary clinical solution including hardware and software components, and uses non-invasive ultrasound-generated data points to manage the cardiovascular needs of CHF patients.
About Bay Tower Group, LLC
Bay Tower Group is a specialized investment bank and strategic advisory firm serving the unique needs of private business owners and middle market companies in the healthcare industry. Bay Tower specializes in mergers, acquisitions, corporate finance, recapitalizations, exit planning and strategic consulting.
About ClearCap Strategic Advisors, LLC
ClearCap Strategic Advisors is a specialized investment bank and strategic advisory firm serving the unique needs of private business owners and middle market companies. ClearCap specializes in mergers, acquisitions, corporate finance, recapitalizations, exit planning and strategic consulting. For more information, visit ClearCap’s website at http://www.clearcapadvisors.com.